# VA Office of Research and Development: Phase 3 study closed enrollment, 378 enrolled (Prostate Cancer, Oligometastasis)

**Score:** 55/100

| Field | Value |
|---|---|
| Sponsor | VA Office of Research and Development |
| Sponsor type | Other federal |
| Study | Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer |
| NCT ID | NCT04787744 |
| Phase | Phase 3 |
| Status | active not recruiting |
| Conditions | Prostate Cancer; Oligometastasis; Oligorecurrence; Recurrent Prostate Cancer; Metastatic Prostate Cancer; De Novo Prostate Cancer |
| Intervention types | procedure, radiation, other, drug |
| Target enrollment | 378 |
| Site countries | United States |
| Posted | 2021-03-09 |
| Planned start | 2021-07-01 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-10-19 |
| Last update posted | 2026-10-19 |

## Why this score
- Enrollment closed: data management, monitoring and closeout ahead.
- Phase 3: multi-site, larger budget.
- 378 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT04787744). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.